clinical trial · NCT07033585
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·phase3·active not recruiting·n = 600
Type 2 DiabetesFarxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetesChina Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
brief summary
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
started
Jun 15, 2025
primary completion
Oct 18, 2026
completion
Nov 28, 2026
last updated
Jul 11, 2025
detailed description
The usual approach group, Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral, 300 double blind random group type 2 diabetes patients with controlled cancers
The study approach group, China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral, 300 double blind random group type 2 diabetes patients with controlled cancers
* Detect Hemoglobin A1c (HbA1c) * Detect fasting blood glucose (FBG) * Detect 2-hour postprandial blood glucose (2 hPBG) * Detect fasting insulin (FINS) * Detect 2-hour postprandial insulin (2 hPINS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol